Golden Metal Resources (GMET), a mineral exploration company, announced exploration results from its Golconda Summit gold project located within the prolific Walker Lane Mineral Belt in Nevada, USA.
Golden Metal Resources (GMET), a mineral exploration company, announced exploration results from its Golconda Summit gold project located within the prolific Walker Lane Mineral Belt in Nevada, USA.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Argos, Contango, First Class,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Advanced Oncotherapy, Angus,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Ananda, Asiamet, Angle,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin,  B90, Deltic, Fresnillo,
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
First Tin (1SN), a tin development company, reported that drilling has proven an 350m extension to the southwest of the current resource area at the Taronga tin project in Australia.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Anglesey,
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is 4D, Goldstone, Horizonte, Kavango, LoopUp, Nostra,
Zak Mir takes a charting look at some of the most followed small caps on the London market. Today’s selection includes  Arrow Exploration, Aura, Bidstack, Cyan, Diurnal, Eco, Galantas, Goldstone,
Open Orphan (ORPH), a rapidly growing specialist contract research organisation announces is growing yet further. hVIVO, a subsidiary of Open Orphan, has signed a £5m respiratory syncytial virus human challenge